Clinical Trial Update: The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating 5-fluorouracil/Mitomycin for hepatocellular carcinoma with pulmonary metastasis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Lung Metastasis

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Mitomycin (Mitomycin)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Hepatocellular Carcinoma, Lung Metastasis | Phase 2 | Status: WITHDRAWN